Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging

Blood

Volumn 94, Issue 2, 1999, Pages 429-433

  Jerusalem, G ^a,b   Beguin, Y ^a   Fassotte, M F ^a   Najjar, F ^a   Paulus, P ^a   Rigo, P ^a   Fillet, G ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b CHU SART TILMAN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; EVALUATION; FEMALE; HODGKIN DISEASE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS;

EID: 0033566341     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v94.2.429.414k26_429_433     Document Type: Article

References (23)

1. Israel O, Front D, Lam M, Ben-Haim S, Kleinhaus U, Ben-Shachar M, Robinson E, Kolodny GM: Ga-67 imaging in monitoring lymphoma response to treatment. Cancer 61:2439, 1988
2. Canellos GP: Residual mass in lymphoma may not be residual disease. J Clin Oncol 6:931, 1988 (editiorial)
3. Rigo P, Paulus P, Kaschten BJ, Hustinx R, Bury T, Jerusalem G, Benoil T, Foidart-Willems J: Oncological applications of positron emission tomography with fluorine-18 fluorodeoxy-glucose. Eur J Nucl Med 23:1641, 1996
4. Warburg O, Wind F, Neglers E: On the metabolism of tumors in the body, in Warburg O (ed): Metabolism of Tumors. London, UK, Constable, 1930, p 254
5. 18 F]-2-deoxy-2-fluoro-D-glucose. J Nucl Med 19:1154, 1978
6. Negendank WG, al-Katib AM, Karanes C, Smith MR: Lymphomas: MR imaging contrast characteristics with clinical-pathologic correlations. Radiology 177:209, 1990
7. Glazer HS, Lee JK, Levitt RG, Heiken JP, Ling D, Totty WG, Balfe DM, Emani B. Wasserman TH, Murphy WA: Radiation fibrosis: Differentiation from recurrent tumor by MR imaging. Radiology 156:721, 1985
8. Nyman RS, Rehn SM, Glimelius BL, Hagberg HE, Hemmingson AL, Sundstrom CJ: Residual mediastinal masses in Hodgkin disease: Prediction of size with MR imaging. Radiology 170:435, 1989
9. Hill M, Cunningham D, Mac Vicar D, Roldan A, Husband J, McCready R, Mansi J, Milan S, Hickish T: Role of magnetic resonance imaging in predicting relapse in residual masses after treatment of lymphoma. J Clin Oncol 11:2273, 1993
10. Devizzi L, Maffioli L, Bonfante V, Viviani S, Balzarini L, Gasparini M, Valagussa P, Bombardieri E, Santoro A, Bonadonna G: Comparison of gallium scan, computed tomography, and magnetic resonance in patients with mediastinal Hodgkin's disease. Ann Oncol 8:S53, 1997 (suppl 1)
11. 67Ga scan versus computed tomography in the staging and in the monitoring of mediastinal malignant lymphoma: A prospective pilot study. MAGMA 4:213, 1996
12. Abrahamsen AF, Lien HH, Aas M, Winderen M, Hager B, Kvaloy S, Elgjo RF, Nome O: Magnetic resonance imaging and 67 gallium scan in mediastinal malignant lymphoma: A prospective pilot study. Ann Oncol 5:433, 1994
13. Zinzani PL, Zompatori M, Bendandi M, Battista G, Fanti S, Barbieri E, Gherlinzoni F, Rimondi MR, Frezza G, Pisi P, Merla E, Gozzetti A, Canini R, Monetti N, Babini L, Tura S: Monitoring bulky mediastinal disease with gallium-67, CT-scan and magnetic resonance imaging in Hodgkin's disease and high-grade non-Hodgkin's lymphoma. Leuk Lymphoma 22:131, 1996
14. Kostakoglu L, Yeh SD, Portlock C, Heelan R, Yao TJ, Niedzwiecki D, Larson SM: Validation of gallium-67-citrate single photon computed tomography in biopsy-confirmed residual Hodgkin's disease in the mediastinum. J Nucl Med 33:345, 1992
15. 3H] deoxyglucose in the tumor model, following chemotherapy and radiotherapy. J Nucl Med 26:278, 1985
16. Front D, Israel O: The role of Ga-67 scintigraphy in evaluating the results of therapy of lymphoma patients. Semin Nucl Med 25:60, 1995
17. Bekerman C, Hoffer PB, Bitran JD: The role of gallium-67 in the clinical evaluation of cancer. Semin Nucl Med 14:296, 1984
18. Kaplan WD, Jochelson MS, Herman TS, Nadler LM, Stomper PC, Takvorian T, Andersen JW, Canellos GP: Gallium-67 imaging: A predictor of residual tumor viability and clinical outcome in patients with diffuse large-cell lymphoma. J Clin Oncol 8:1966, 1990
19. Shin MS, Ho KJ: Diffuse thymic hyperplasia following chemotherapy for nodular sclerosing Hodgkin's disease: An immunologic rebound phenomenon? Cancer 51:30, 1983
20. Peylan-Ramu N, Haddy TB, Jones E, Horvath K, Adde MA, Magrath IT: High frequency of benign mediastinal uptake of gallium-67 after completion of chemotherapy in children with high-grade non-Hodgkin's lymphoma. J Clin Oncol 7:1800, 1989
21. Weinblatt ME, Zanzi I, Belakhlef A, Babchyck B, Kochen J: False-positive FDG-PET imaging of the thymus of a child with Hodgkin's disease. J Nucl Med 38:888, 1997
22. th Annual Meeting of the Society of Nuclear Medicine, San Antonio, Texas. J Nucl Med 38:154P, 1997
23. De Wit M, Bumann D, Beyer W, Herbst K, Clausen M, Hossfeld DK: Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma. Ann Oncol 8:S57, 1997 (suppl 1 )